Di Tillio-Gonzalez Dannie, Fischbach Ruth L
Center for Bioethics, Columbia University, New York, NY 10032USA.
Dev World Bioeth. 2008 Dec;8(3):167-77. doi: 10.1111/j.1471-8847.2006.00174.x. Epub 2006 Oct 13.
This article aims to compare the national legal systems that regulate biomedical research in an industrialized country (United States) and a developing country (Venezuela). A new international order is emerging in which Europe, Japan and the United States (US) are revising common guidelines and harmonizing standards. In this article, we analyze - as an example - the US system. This system is controlled by a federal agency structured to regulate research funded by the federal government uniformly, either in the US or abroad. In contrast, in Venezuela, a developing country, the creation of a centralized system is a slow process. Different types of ethical committees review research projects using non-uniform criteria. Consequently, various parallel organizations that conduct biomedical research, such as universities, research institutes and private hospitals have diverse regulations operating at a local level. Thus, the most relevant difference between the Venezuelan and the US systems is the degree of standardization. In the US, the review process is performed by institutional review boards (IRBs), which have a similar organization and maintain relationships with a centralized agency, following standard regulations. Although new proposals for establishing national regulations are currently being considered in Venezuela, the success of these initiatives will depend on promoting governmental efforts to create a more structured centralized system supported by a national regulatory framework. This system will need governmental financial support at all levels. This article proposes an integrated system to regulate research with human participants in Venezuela and other developing countries.
本文旨在比较工业化国家(美国)和发展中国家(委内瑞拉)规范生物医学研究的国家法律制度。一个新的国际秩序正在形成,欧洲、日本和美国正在修订共同准则并统一标准。在本文中,我们以美国制度为例进行分析。该制度由一个联邦机构控制,该机构旨在统一规范由联邦政府资助的在美国境内或境外开展的研究。相比之下,在发展中国家委内瑞拉,建立一个集中化体系是一个缓慢的过程。不同类型的伦理委员会使用不一致的标准审查研究项目。因此,开展生物医学研究的各类平行组织,如大学、研究机构和私立医院,在地方层面有着不同的规定。所以,委内瑞拉和美国制度之间最显著的差异在于标准化程度。在美国,审查过程由机构审查委员会(IRB)进行,这些委员会有着相似的组织架构,并遵循标准规定与一个中央机构保持联系。尽管委内瑞拉目前正在考虑制定国家法规的新提案,但这些举措能否成功将取决于推动政府努力创建一个由国家监管框架支持的、结构更完善的集中化体系。这个体系需要各级政府的财政支持。本文提出了一个综合体系,用于规范委内瑞拉及其他发展中国家涉及人类受试者的研究。